Deuterx
Andover, US · Founded 2012 · Delaware LLC
Find your way into Deuterx
106 people in our graph share verified history with the Deuterx team — schools, employers, funds. One of them is your warm intro.
Mike Zakunlockedknows Sheila DeWitt · together at Cornell (overlapped)
×2knows the team · via Cornell
×8knows the team · via Duke University
knows the team · via FMC Corporation
Founders & leadership
Deuterx was founded in 2012 by Sheila DeWitt.
SD
Sheila DeWittinChair, President, CEO & FounderSheila DeWitt is an executive with experience leading drug discovery and development initiatives, including managing multiple biotechnology companies and business units, overseeing deuterated drug portfolio sales to public companies, and directing substantial M&A transactions and R&D operations.
Board
AW
Anthony W. CzarnikBoard director
Reported raises · per SEC filings
Form D private placements$2.2M disclosed across 1 round · 2015
▶$2.2MraisedSep 2015 · 26 investors · BiotechnologyRule 506(b)
▶$2.2MraisedSep 2015 · 26 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Sheila DeWittExecutive Officer, Director
- Anthony W. CzarnikDirector
- Amount sold
- $2.2M
- First sale
- Sep 2015
- Incorporated
- Limited Liability Company, Delaware, 2012
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 4
by search overlapBuilding Engines3 shared keywordsBuilding Engines is a cloud building operations platform for commercial real estate, acquired by JLL in 2021 for about $300 million.
Delix3 shared keywordsDelix Therapeutics develops third-generation, non-hallucinogenic neuroplastogens for people with neurological conditions, using a discovery platform to identify novel compounds. Its pipeline includes a Phase 2-ready asset and multiple preclinical programs targeting brain health and neuroplasticity.
Nurix Therapeutics3 shared keywordsNurix Therapeutics develops protein degrader-based medicines using proprietary DEL-AI discovery technology to address cancer and autoimmune diseases. The company applies targeted protein degradation to overcome limitations of conventional therapeutic approaches.
Redfin3 shared keywordsReal Estate & Homes for Sale, Rentals, Mortgages & Agents
Companies competing with Deuterx for the same Google search keywords, organic and paid, via search-intersection analysis.
Non-dilutive funding · 1 SBIR/STTR award
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2016 | $294.5K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
Frequently asked questions
- Who founded Deuterx?
- Deuterx was founded by Sheila DeWitt in 2012.
- How much funding has Deuterx raised?
- Deuterx has disclosed $2.2M raised across 1 round.
- Where is Deuterx headquartered?
- Deuterx is headquartered in Andover, US.